ArticleFrontiers in endocrinology2026
Efficacy of letrozole combined with recombinant human growth hormone in boys aged ≥10 years with advanced bone age and impaired growth potential: a retrospective cohort study.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: In boys aged ≥10 years with advanced bone age and impaired growth potential (baseline height SDS < -1.5, BA-CA ≥1.5 years, and PAH < -2 SDS), growth hormone monotherapy, while promoting linear growth, fails to delay skeletal maturation, thus limiting therapeutic efficacy. Although letrozole combined with growth hormone may theoretically "decouple" height gain from epiphyseal closure, high-quality evidence specific to the advanced bone age population remains insufficient, and concerns regarding baseline bias and lack of long-term safety data persist. This study, based on real-world data, aims to clarify the benefits and risks of this combination regimen in promoting linear growth, delaying bone age progression, and improving adult height outcomes. Methods: A retrospective analysis was conducted on clinical data from 64 boys aged ≥10 years with advanced bone age and impaired growth potential treated in our hospital from June 2020 to December 2025 (baseline height SDS < -1.5, BA-CA ≥1.5 years, and PAH < -2 SDS). Patients were divided into a combination therapy group (letrozole + rhGH, n = 36) and a monotherapy group (rhGH alone, n = 28) according to treatment regimen. Changes in height, bone age, annual growth velocity, the ratio of bone age advancement to chronological age progression (ΔBA/ΔCA), and sex hormone levels were compared between the two groups before and after treatment. Results: The mean annual growth velocity in the combination group was (7.7 ± 1.2) cm/year, significantly higher than that in the monotherapy group [(6.7 ± 1.4) cm/year, Discussion: In boys aged ≥10 years with advanced bone age and impaired growth potential, letrozole combined with rhGH significantly improved annual growth velocity and delayed bone age progression compared with rhGH monotherapy. However, the difference in final adult height among those who completed treatment was not statistically significant (1.4 cm, P = 0.291). The significantly better control of bone age advancement (ΔBA/ΔCA) and higher target-height attainment rate suggest a potential benefit of adding letrozole, but larger studies with more participants reaching final height are needed to confirm a meaningful effect on adult height.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.